journal article·2024-09Open access

Intraoperative Resection Guidance and Rapid Pathological Diagnosis of Osteosarcoma using B7H3 Targeted Probe under NIR‐II Fluorescence Imaging

Fanwei Zeng, Changjian Li, Han Wang, Yueqi Wang, Tingting Ren, Fangzhou He, Jie Jiang, Jiuhui Xu, Boyang Wang, Yifan Wu, Yiyang Yu, Zhenhua Hu, Jie Tian, Shidong Wang, Xiaodong Tang

Advanced Science· Volume 11· Issue 33

Abstract

Abstract Complete removal of all tumor tissue with a wide surgical margin is essential for the treatment of osteosarcoma (OS). However, it's difficult, sometimes impossible, to achieve due to the invisible small satellite lesions and blurry tumor boundaries. Besides, intraoperative frozen‐section analysis of resection margins of OS is often restricted by the hard tissues around OS, which makes it impossible to know whether a negative margin is achieved. Any unresected small tumor residuals will lead to local recurrence and worse prognosis. Herein, based on the high expression of B7H3 in OS, a targeted probe B7H3‐IRDye800CW is synthesized by conjugating anti‐B7H3 antibody and IRDye800CW. B7H3‐IRDye800CW can accurately label OS areas after intravenous administration, thereby helping surgeons identify and resect residual OS lesions (<2 mm) and lung metastatic lesions. The tumor‐background ratio reaches 4.42 ± 1.77 at day 3. After incubating fresh human OS specimen with B7H3‐IRDye800CW, it can specifically label the OS area and even the microinvasion area (confirmed by hematoxylin‐eosin [HE] staining). The probe labeled area is consistent with the tumor area shown by magnetic resonance imaging and complete HE staining of the specimen. In summary, B7H3‐IRDye800CW has translational potential in intraoperative resection guidance and rapid pathological diagnosis of OS.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Advanced biosensing and bioanalysis techniques · Peptidase Inhibition and Analysis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Musculoskeletal Tumor & Beijing Key Laboratory of Musculoskeletal Tumor Peking University People's Hospital Beijing 100044 China

School of Engineering Medicine & Key Laboratory of Big Data‐Based Precision Medicine Beihang University Ministry of Industry and Information Technology Beijing 100191 China

CAS Key Laboratory of Molecular Imaging Beijing Key Laboratory of Molecular Imaging Institute of Automation Chinese Academy of Sciences Beijing 100190 China

Funding

National Natural Science Foundation of China · Natural Science Foundation of Beijing Municipality · Fundamental Research Funds for the Central Universities

References (52)

Show source-provided references
1. 10.1002/cncr.3416310.1002/cncr.34163 ↗
2. 10.1056/NEJMra210342310.1056/NEJMra2103423 ↗
3. 10.1002/pbc.2442910.1002/pbc.24429 ↗
4. 10.3109/0284186X.2014.92393410.3109/0284186X.2014.923934 ↗
5. 10.1097/01.JAA.0000541477.24116.8d10.1097/01.JAA.0000541477.24116.8d ↗
6. 10.1586/era.10.17210.1586/era.10.172 ↗
7. 10.1302/0301-620X.84B3.084039510.1302/0301-620X.84B3.0840395 ↗
8. 10.1007/s00259-022-05975-710.1007/s00259-022-05975-7 ↗
9. 10.1016/j.ebiom.2023.10447610.1016/j.ebiom.2023.104476 ↗
10. 10.3390/cancers1602027510.3390/cancers16020275 ↗
11. 10.1038/nrc383810.1038/nrc3838 ↗
12. 10.1200/JCO.2014.59.489510.1200/JCO.2014.59.4895 ↗
13. 10.1002/smtd.20200106610.1002/smtd.202001066 ↗
14. 10.1007/s11060-021-03718-610.1007/s11060-021-03718-6 ↗
15. 10.1038/s44222-022-00017-110.1038/s44222-022-00017-1 ↗
16. 10.1016/S1470-2045(19)30317-110.1016/S1470-2045(19)30317-1 ↗
17. 10.1302/0301-620X.105B5.BJJ-2022-0803.R110.1302/0301-620X.105B5.BJJ-2022-0803.R1 ↗
18. 10.1016/j.ygyno.2019.03.25210.1016/j.ygyno.2019.03.252 ↗
19. 10.1158/1078-0432.CCR-16-043710.1158/1078-0432.CCR-16-0437 ↗
20. 10.7150/thno.2448710.7150/thno.24487 ↗
21. 10.1016/S2468-1253(17)30395-310.1016/S2468-1253(17)30395-3 ↗
22. 10.18632/oncotarget.828210.18632/oncotarget.8282 ↗
23. 10.1016/j.biomaterials.2011.10.00510.1016/j.biomaterials.2011.10.005 ↗
24. 10.1158/1078-0432.CCR-12-359810.1158/1078-0432.CCR-12-3598 ↗
25. 10.1039/C8SC01153B10.1039/C8SC01153B ↗
26. 10.1088/0031-9155/58/11/R3710.1088/0031-9155/58/11/R37 ↗
27. 10.1039/D2CS00131D10.1039/D2CS00131D ↗
28. 10.1016/j.ebiom.2023.10488010.1016/j.ebiom.2023.104880 ↗
29. 10.1158/1078-0432.CCR-20-258410.1158/1078-0432.CCR-20-2584 ↗
30. 10.1038/cr.2017.9010.1038/cr.2017.90 ↗
31. 10.1371/journal.pone.007068910.1371/journal.pone.0070689 ↗
32. 10.1158/1078-0432.CCR-18-043210.1158/1078-0432.CCR-18-0432 ↗
33. 10.1159/00044785910.1159/000447859 ↗
34. 10.1002/ijc.2623810.1002/ijc.26238 ↗
35. 10.1158/2159-8290.CD-22-075010.1158/2159-8290.CD-22-0750 ↗
36. 10.1038/s41591-023-02284-w10.1038/s41591-023-02284-w ↗
37. 10.1158/1078-0432.CCR-20-422110.1158/1078-0432.CCR-20-4221 ↗
38. 10.3390/biomedicines910138810.3390/biomedicines9101388 ↗
39. 10.1002/advs.20220643510.1002/advs.202206435 ↗
40. 10.1016/S2468-1253(16)30082-610.1016/S2468-1253(16)30082-6 ↗
41. 10.1155/2022/169382410.1155/2022/1693824 ↗
42. 10.1016/j.jconrel.2023.08.05610.1016/j.jconrel.2023.08.056 ↗
43. 10.1002/adma.20230190110.1002/adma.202301901 ↗
44. 10.1021/acs.nanolett.3c0497610.1021/acs.nanolett.3c04976 ↗
45. 10.1016/j.bios.2022.11470110.1016/j.bios.2022.114701 ↗
46. 10.1016/j.bios.2022.11462010.1016/j.bios.2022.114620 ↗
47. 10.1016/j.ctrv.2013.11.00610.1016/j.ctrv.2013.11.006 ↗
48. 10.1200/JCO.20.0197410.1200/JCO.20.01974 ↗
49. 10.1016/S2468-1253(20)30088-110.1016/S2468-1253(20)30088-1 ↗
50. 10.2967/jnumed.122.26513110.2967/jnumed.122.265131 ↗
51. 10.1186/s12885-021-08003-310.1186/s12885-021-08003-3 ↗
52. 10.1002/admi.20210185510.1002/admi.202101855 ↗